Definium Therapeutics (DFTX) Retained Earnings (2020 - 2026)

Definium Therapeutics (DFTX) has reported Retained Earnings for 7 consecutive years, with -$659.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 56.28% year-over-year to -$659.8 million; the TTM figure through Mar 2026 stood at -$659.8 million (down 56.28% YoY), while the FY2025 annual figure was -$582.7 million, down 46.08% from the prior year.
• Retained Earnings retreated to -$659.8 million in Q1 2026 per DFTX's latest filing, from -$582.7 million in the prior quarter.
• Across five years, Retained Earnings topped out at $850000.0 in Q2 2022 and bottomed at -$659.8 million in Q1 2026.
• Historically, Retained Earnings has averaged -$268.3 million across 5 years, with a median of -$248.4 million in 2023.
• Annual changes were most pronounced in 2023 — Retained Earnings jumped 100.41% — and 2024, when it slumped 116391.25%.
• Definium Therapeutics' Retained Earnings stood at -$194.5 million in 2022, then soared by 100.18% to $343000.0 in 2023, then plunged by 116391.25% to -$398.9 million in 2024, then tumbled by 46.08% to -$582.7 million in 2025, then decreased by 13.24% to -$659.8 million in 2026.
• Business Quant data shows DFTX's Retained Earnings at -$659.8 million in Q1 2026, -$582.7 million in Q4 2025, and -$532.2 million in Q3 2025.